Lawnwood Regional Medical Center & Heart Institute Acquires Mazor Robotics’ Renaissance System

CAESAREA, Israel –(BUSINESS WIRE)–Mazor Robotics Ltd. (TASE:MZOR; NASDAQCM:MZOR), the developer of Renaissance®, an innovative surgical guidance system and its complementary products, announced today that Lawnwood Regional Medical Center & Heart Institute, located in Ft. Pierce, FL, has purchased its first Renaissance system.

“I am excited to see the continued adoption of our Renaissance technology in new hospitals,” commented Ori Hadomi, President and Chief Executive Officer. “I am confident that Lawnwood Regional Medical Center & Heart Institute, through this purchase, will experience the clinical and economic benefits of Renaissance, as have the other hospitals that are already utilizing Renaissance. It will become a member of a growing community of Robotic Spine surgery leaders, who are committed to creating value and improving clinical outcomes through these advanced technologies.” 

“We are proud to be the first to offer the Mazor to the communities of the Treasure and Central Coast,” says Stephen J. Daugherty, Interim Chief Executive Officer of Lawnwood Regional Medical Center & Heart Institute. “This pioneering technology will allow our surgeons to more accurately and efficiently perform the simplest to the most complex spine surgeries as well as treat disorders deep within the brain. Renaissance’s state-of-the art technology is ultimately about providing the best patient care. This highly-accurate robotic system can enable a faster recovery for our patients.”

Lawnwood Regional Medical Center & Heart Institute is a 370-bed, tertiary care facility that receives patients from throughout the region. Home to the Treasure Coast Trauma Center, it provides life-saving care for patients with critical or traumatic injuries from St. Lucie, Indian River, Okeechobee, and Martin counties. It is part of one of the nation’s leading providers of healthcare services, comprised of locally managed facilities that include about 162 hospitals and 113 freestanding surgery centers.

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the expectations for growth in system sales and recurring revenue, the Company’s expected sales in 2016, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on April 29, 2015 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

U.S. Contacts: EVC Group

Michael Polyviou/Doug Sherk – Investors

212.850.6020; 646-445-4800

David Schemelia – Media



Latest Tweet

Mazor #CoreTechnology can help you produce consistent results that lead to improved clinical outcomes. Get more inf…
Follow Mazor Robotics on Twitter
©2018 Mazor Robotics. All Rights Reserved. Designed By Medtech Momentum